{"id":960929,"date":"2026-05-11T16:28:17","date_gmt":"2026-05-11T20:28:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/"},"modified":"2026-05-11T16:28:17","modified_gmt":"2026-05-11T20:28:17","slug":"aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/","title":{"rendered":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments<\/li>\n<li>Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027<\/li>\n<li>Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual Meeting<\/li>\n<li>Enrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027\n<\/li>\n<\/ul>\n<p>BOSTON, May  11, 2026  (GLOBE NEWSWIRE) &#8212; Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026.<\/p>\n<p>&#8220;We continue to build momentum toward delivering a new class of radiopharmaceuticals targeting tumor types with large patient populations, leveraging our differentiated miniprotein radioconjugate platform and patient-first end-to-end supply chain,\u201d said Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology. \u201cLast week, we announced the initiation of our Phase 1b clinical trial of AKY-2519 in patients with mCRPC. This is the first of two trials in our clinical development strategy designed to expand the breadth of tumors studied and augment speed to data, with preliminary data from the mCRPC trial anticipated in 2027. We plan to initiate a second Phase 1b basket trial of AKY-2519 in additional solid tumors in the second half of this year. We also look forward to presenting our first AKY-2519 clinical imaging and dosimetry data for AKY-2519 at ASCO, which informed our clinical development strategy.\u201d<\/p>\n<p>Dr. Roden continued, \u201cAKY-2519 marks the second program we have advanced from our proprietary miniprotein radioconjugate platform to the clinic in the last twelve months. In parallel, we continue to enroll patients in our ongoing Phase 1b trial of AKY-1189 targeting Nectin-4 expressing tumors, with preliminary data expected in the first quarter of 2027. We remain focused on generating clinical data intended to support advancement of both programs and maximizing the potential clinical benefit for patients.\u201d<\/p>\n<p>\n        <strong>Q1 and recent business highlights <\/strong>\n      <\/p>\n<p>\n        <strong>AKY-1189 highlights<\/strong>\n      <\/p>\n<p>AKY-1189 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver actinium-225 (<sup>225<\/sup>Ac) to Nectin-4 expressing tumors.<\/p>\n<ul type=\"disc\">\n<li>Received Fast Track designation from the U.S. Food and Drug Administration (FDA) for AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed on or after prior systemic therapies.<\/li>\n<li>Enrolling patients in the ongoing Phase 1b clinical trial of AKY-1189 in patients with locally advanced or mUC, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.<\/li>\n<li>Expect to report preliminary data from the Phase 1b trial in the first quarter of 2027.\n<\/li>\n<\/ul>\n<p>\n        <strong>AKY-2519<\/strong><br \/>\n        <strong>highlights<\/strong>\n      <\/p>\n<p>AKY-2519 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver <sup>225<\/sup>Ac to B7-H3 expressing tumors, including prostate, lung, and other solid tumors.<\/p>\n<ul type=\"disc\">\n<li>Received FDA clearance for the Company\u2019s Investigational New Drug (IND) applications to proceed to a Phase 1b clinical trial with AKY-2519<sup>1<\/sup>.<\/li>\n<li>Announced two-trial clinical development strategy for AKY-2519, which was informed by insights from the Company\u2019s clinical advisory boards and reflects the distinct treatment patterns and clinical needs of patients with mCRPC compared to other solid tumor patients. This strategy is designed to enable the broad evaluation of AKY-2519 in multiple patient segments while efficiently generating indication-relevant data.<\/li>\n<li>Initiated Phase 1b, multicenter, open label clinical trial of AKY-2519 in PLUVICTO\u00ae-na\u00efve and PLUVICTO-experienced patients with mCRPC.<\/li>\n<li>Plan to initiate a Phase 1b basket trial in patients with lung, colorectal, and other B7-H3 expressing solid tumors in the second half of 2026. The protocol for this trial has been finalized and is currently under regulatory review.<\/li>\n<li>Announced clinical imaging and dosimetry data for AKY-2519 has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 \u2013 June 2, 2026, in Chicago. The data facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal tissues in patients with B7-H3 expressing solid tumors.<\/li>\n<\/ul>\n<p>\n        <sup>1<\/sup> IND applications were cleared for [<sup>64<\/sup>Cu]Cu-AKY-2519 for imaging and [<sup>225<\/sup>Ac]Ac-AKY-2519 for therapeutic use.<\/p>\n<p>\n        <strong>General corporate highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Appointed industry veteran Glenn Gormley, MD, PhD as an independent director to the Company\u2019s Board of Directors (Board) and as co-chair of the Board\u2019s newly established Science and Technology Committee.<\/li>\n<li>In January 2026, completed an initial public offering of 20,297,500 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,647,500 shares of common stock, at $18.00 per share, resulting in gross proceeds of approximately $365.4 million, before deducting underwriting discounts and commissions and other offering expenses.\n<\/li>\n<\/ul>\n<p>\n        <strong>Anticipated pipeline and corporate milestones for the next 12 months<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>AKY-1189:<\/strong> Expect preliminary data from the ongoing Phase 1b clinical trial in the first quarter of 2027.<\/li>\n<li>\n          <strong>AKY-2519:<\/strong><\/p>\n<ul type=\"disc\">\n<li>Will present clinical imaging and dosimetry data of AKY-2519 in patients with mCRPC and various solid tumors at the upcoming ASCO Annual Meeting.<\/li>\n<li>Expect to commence Phase 1b basket trial in lung, colorectal, and other solid tumor cancers in the second half of 2026.<\/li>\n<li>Expect preliminary data from the Phase 1b mCRPC clinical trial in 2027.<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Early pipeline:<\/strong> Two programs are tracking toward development candidate nomination and commencement of IND-enabling activities in the first quarter of 2027.<\/li>\n<li>\n          <strong>Corporate:<\/strong> In-house Good Manufacturing Practices (GMP) facility expected to be operational in the second half of 2026 as part of the Company\u2019s hybrid manufacturing strategy to expand capabilities and support clinical supply demand.<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>First quarter 2026 financial results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Cash position: <\/strong>Cash, cash equivalents and marketable securities were $538.5 million as of March 31, 2026, compared to $226.8 million as of December 31, 2025. The increase of $311.7 million primarily reflects net proceeds from the Company\u2019s initial public offering in January 2026, primarily offset by cash used in operations. The Company\u2019s cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund its operations into 2029.<\/li>\n<li>\n          <strong>Collaboration revenue: <\/strong>Collaboration revenue was $3.2 million for the quarter ended March 31, 2026, compared to $1.4 million for the comparable prior year period. The increase of $1.8 million was attributable to continued advancement of the Company\u2019s research collaboration with Eli Lilly and Company, with revenue recognized over time using the cost incurred input method.<\/li>\n<li>\n          <strong>R&amp;D expenses: <\/strong>Research and development expenses were $20.0 million for the quarter ended March 31, 2026, compared to $15.9 million for the comparable prior year period. The increase of $4.1 million was primarily driven by Phase 1b clinical trial expenses for AKY-1189, which initiated in the second quarter of 2025, increased expenses with advancing AKY-2519 through IND-enabling studies, and increased employee-related costs (including stock-based compensation) associated with increased hiring to support the advancing clinical pipeline.<\/li>\n<li>\n          <strong>G&amp;A expenses: <\/strong>General and administrative expenses were $5.9 million for the quarter ended March 31, 2026, compared to $3.7 million for the comparable prior year period. The increase of $2.2 million was primarily due to higher employee-related costs (including stock-based compensation) related to increased hiring to support the Company\u2019s growth, and increased expenses associated with operating as a public company.<\/li>\n<li>\n          <strong>Net loss: <\/strong>Net loss was $18.3 million for the quarter ended March 31, 2026, compared to $15.0 million for the comparable prior year period. The increase in net loss of $3.3 million was primarily driven by increased operating expenses. <\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>About Aktis\u2019 miniprotein radioconjugate platform<\/strong><br \/>\n        <br \/>Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis\u2019 therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end supply chain, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.<\/p>\n<p>\n        <strong>About Aktis Oncology<\/strong><br \/>\n        <br \/>Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis\u2019 most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis\u2019 second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, colorectal, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis\u2019 miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fqp8-N81emmKOphoVhsKZw6Y6LAYdwFpMWKMedmOSq64I_YsZziBydR7b90JCIVrCjfIT2tf5zN3RXRkkNTrCw5tb7MvCyD-Uc1xTYWLcOc=\" rel=\"nofollow\" target=\"_blank\">www.aktisoncology.com<\/a>.<\/p>\n<p>\n        <strong>Forward-looking statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company\u2019s expectations about the timing of ongoing and planned clinical trials and regulatory filings, goals to develop and commercialize its product candidates, its liquidity and capital resources, and other statements identified by words such as \u201ccould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company\u2019s control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to the Company\u2019s limited operating history, its ability to obtain necessary funding, its ability to generate positive clinical trial results for its product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which the Company is subject, competitive pressures, its ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading \u201cRisk Factors\u201d of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequent filings with the Securities and Exchange Commission. The Company\u2019s actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise these forward-looking statements.<\/p>\n<p>\n        \n      <\/p>\n<p>\n        \n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center;vertical-align: middle\">\n            <strong>AKTIS ONCOLOGY, INC.<br \/>CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS<br \/><\/strong>(In thousands, except shares and par value data) <br \/>(Unaudited)<strong><br \/><\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"6\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Three Months Ended March\u00a031,<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Revenue:<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:58%;width:58%;min-width:58%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Collaboration revenue<\/td>\n<td style=\"max-width:3%;width:3%;min-width:3%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,227<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,447<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Operating expenses:<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Research and development<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">20,036<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">15,863<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">General and administrative<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">5,897<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">3,727<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Total operating expenses<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">25,933<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">19,590<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Loss from operations<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(22,706<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(18,143<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Other income (expense):<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Interest income<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">4,384<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">3,171<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other expense, net<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(3<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(13<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Total other income, net<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">4,381<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">3,158<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Net loss<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(18,325<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,985<\/td>\n<td style=\"vertical-align: bottom\">)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong><\/p>\n<p>        <\/strong>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"width:99.6687%;text-align: center;vertical-align: middle\">\n            <strong>AKTIS ONCOLOGY, INC.<\/strong><br \/>\n            <br \/>\n            <strong>BALANCE SHEET DATA<\/strong><br \/>\n            <br \/>(In thousands, except shares and par value data) <br \/>(Unaudited)<\/td>\n<td style=\"width:0.350329%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.18956%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.072%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>March\u00a031,<\/strong>\n          <\/td>\n<td style=\"width:0.350329%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:14.1008%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>December\u00a031,<\/strong>\n          <\/td>\n<td style=\"width:0.350329%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.18956%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.072%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"width:0.350329%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:14.1008%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:0.350329%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: top\">Cash, cash equivalents and marketable securities<\/td>\n<td style=\"width:2.18956%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.57648%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.49549%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">538,484<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.27714%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.8236%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">226,787<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: top\">Total assets<\/td>\n<td style=\"width:2.18956%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.57648%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.49549%;text-align: right;vertical-align: middle;vertical-align: bottom\">576,801<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.27714%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.8236%;text-align: right;vertical-align: middle;vertical-align: bottom\">264,885<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: top\">Total liabilities<\/td>\n<td style=\"width:2.18956%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.57648%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.49549%;text-align: right;vertical-align: middle;vertical-align: bottom\">70,693<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.27714%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.8236%;text-align: right;vertical-align: middle;vertical-align: bottom\">77,625<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:72.6058%;vertical-align: top\">Total stockholders&#8217; equity (deficit) and redeemable convertible preferred stock<\/td>\n<td style=\"width:2.18956%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.57648%;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.49549%;text-align: right;vertical-align: middle;vertical-align: bottom\">506,108<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.350329%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.27714%;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.8236%;text-align: right;vertical-align: middle;vertical-align: bottom\">187,260<\/td>\n<td style=\"width:0.350329%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Media contact:<\/strong><br \/>\n        <br \/>Melone Communications, LLC<br \/>Liz Melone<br \/>617-256-6622<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Qq1wT1ZIDCxnObrRT5h7yMXOcmu_G6Uv8f8L-E4y4a8NMPqvg-t51_YUGfeCXeGNrUQZ2VshrYRmo0FezcMTqCiQAAtVU83x0LIvMS6vao=\" rel=\"nofollow\" target=\"_blank\"><u>liz@melonecomm.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor contact:<\/strong><br \/>\n        <br \/>Precision AQ<br \/>Alex Lobo<br \/>212-698-8802<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_d4SUfWO4vAIVYE6zutWcPMVNiUpK3QS_W4Tw-4P4WDPG-DQhCpXktIRGhGUihTAkYWUZH0kxN2Df7kKA4xCPoz3aXtxscBzqoWLItihaT0DDpBWJ4O5075WdWuYMNPL\" rel=\"nofollow\" target=\"_blank\"><u>Alex.lobo@precisionaq.com<\/u><\/a><\/p>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmEzMTg5ZjAtZTNjZi00MzUzLWJlZjMtMDVhYWJiM2RiNGY3LTEzMDY3NDktMjAyNi0wNS0xMS1lbg==\/tiny\/Aktis-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual Meeting Enrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) &#8212; Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-960929","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual Meeting Enrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) &#8212; Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026. &hellip; Continue reading &quot;Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T20:28:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026\",\"datePublished\":\"2026-05-11T20:28:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/\"},\"wordCount\":1816,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/\",\"name\":\"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\",\"datePublished\":\"2026-05-11T20:28:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/","og_locale":"en_US","og_type":"article","og_title":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk","og_description":"Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual Meeting Enrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) &#8212; Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026. &hellip; Continue reading \"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-11T20:28:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026","datePublished":"2026-05-11T20:28:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/"},"wordCount":1816,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/","name":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=","datePublished":"2026-05-11T20:28:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzU0MSM3NTk1Njk4IzIyOTUxOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=960929"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960929\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=960929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=960929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=960929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}